127 related articles for article (PubMed ID: 28798068)
1. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
Strati P; Keating MJ; Burger JA; O'Brien SM; Wierda WG; Estrov Z; Zacharian G; Ferrajoli A
Haematologica; 2017 Dec; 102(12):e494-e496. PubMed ID: 28798068
[No Abstract] [Full Text] [Related]
2. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt TD; Ramsay AG; Zent CS; Leis JF; Tun HW; Call TG; LaPlant B; Bowen D; Pettinger A; Jelinek DF; Hanson CA; Kay NE
Blood; 2013 May; 121(20):4137-41. PubMed ID: 23493782
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
4. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Strati P; Ferrajoli A; Wierda WG; Jain N; Thompson PA; O'Brien SM; Rezvani K; Kantarjian HM; Burger JA; Hinojosa CO; Keating MJ; Estrov Z
Leukemia; 2018 Oct; 32(10):2278-2281. PubMed ID: 29479067
[No Abstract] [Full Text] [Related]
5. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
7. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Fürstenau M; Fink AM; Schilhabel A; Weiss J; Robrecht S; Eckert R; de la Serna J; Crespo M; Coscia M; Vitale C; Böttcher S; Weppner G; Ritgen M; Stilgenbauer S; Tausch E; Fischer K; Hallek M; Eichhorst B; Brüggemann M; Herling CD
Blood; 2021 Apr; 137(16):2267-2271. PubMed ID: 33512465
[No Abstract] [Full Text] [Related]
8. Jump-starting the T cells in CLL.
Johnston JB
Blood; 2013 May; 121(20):4016-7. PubMed ID: 23682029
[TBL] [Abstract][Full Text] [Related]
9. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.
Reljic T; Kumar A; Djulbegovic B; Kharfan-Dabaja MA
Bone Marrow Transplant; 2015 Aug; 50(8):1069-74. PubMed ID: 25867647
[TBL] [Abstract][Full Text] [Related]
10. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
Al-Sawaf O; Robrecht S; Bahlo J; Fink AM; Cramer P; von Tresckow J; Maurer C; Bergmann M; Seiler T; Lange E; Kneba M; Stilgenbauer S; Döhner H; Kiehl MG; Jäger U; Wendtner CM; Fischer K; Goede V; Hallek M; Eichhorst B; Hopfinger G
Leukemia; 2017 Oct; 31(10):2251-2253. PubMed ID: 28745332
[No Abstract] [Full Text] [Related]
11. The evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.
Lamanna N
Clin Adv Hematol Oncol; 2016 Oct; 14(10):756-758. PubMed ID: 27930625
[No Abstract] [Full Text] [Related]
12. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
13. Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?
Brown JR; Wierda WG
J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1408-1410. PubMed ID: 31766019
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
Al-Sawaf O; Fischer K; Herling CD; Ritgen M; Böttcher S; Bahlo J; Elter T; Stilgenbauer S; Eichhorst BF; Busch R; Elberskirch U; Abenhardt W; Kneba M; Hallek M; Wendtner CM
Eur J Haematol; 2017 Mar; 98(3):254-262. PubMed ID: 27862308
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia.
Brown JR; Kay NE
J Clin Oncol; 2017 Sep; 35(26):2989-2992. PubMed ID: 28742455
[No Abstract] [Full Text] [Related]
16. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
[TBL] [Abstract][Full Text] [Related]
18. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
20. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
